Low-dose aspirin and risks of cataract in a randomized trial of US physicians
J. M. Seddon, W. G. Christen, J. E. Manson, J. E. Buring, R. D. Sperduto and C. H. Hennekens
Epidemiology Unit, Massachusetts Eye and Ear Infirmary, Boston.
Observational studies have raised the question of a possible benefit of
aspirin on the development of cataract. The Physicians' Health Study, a
randomized double-masked placebo-controlled trial among 22,071 male
physicians, aged 40 to 84 years, provided the opportunity to collect
information about whether low-dose aspirin therapy (325 mg on alternate
days) affects the development or extraction of cataract. There were 173
age-related cataracts among those physicians assigned to aspirin therapy
and 180 among those given placebo (relative risk, 0.95; 95% confidence
interval, 0.74 to 1.22). Cataract extractions were less frequent in the
aspirin than in the placebo group, but this difference was not
statistically significant (relative risk, 0.80; 95% confidence interval,
0.56 to 1.15). Among younger men (aged 40 to 59 years), the relative risks
were 0.62 (95% confidence interval, 0.40 to 0.94) for cataract development
and 0.67 (95% confidence interval, 0.38 to 1.31) for cataract extraction.
These randomized trial data tend to exclude any large benefit of aspirin.
While the overall findings concerning cataract development seem to be null,
the data on extraction of age-related cataract, while not statistically
significant, cannot exclude a possible small to moderate benefit of
alternate-day aspirin therapy on the extraction of age-related cataract.
